Needham analyst Rajvindra Gill downgrades Silicon Laboratories (NASDAQ:SLAB) from Buy to Hold.
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd). The data showed encouraging and…